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Previous studies conducted with the imidazolidinic derivative 3-benzyl-5-(4-chloro-arylazo)-4-thioxo-imidazolidin-2-one (LPSF-
PT05) show outstanding activity against adult Schistosoma mansoni worms in vitro. In the ﬁrst phase of this study, S. mansoni-
infected mice were treated, orally, with 100mg/Kg of the LPSF-PT05 in three formulations: Tween 80 and saline solution, oil/water
(70:30)emulsion,andsoliddispersionwithpolyethyleneglycol(PEG).Inthesecondphase,threeotherdosesoftheLPSF-PT05in
PEG were tested: 3, 10, 30mg/kg. These treatment regimens signiﬁcantly reduced the number of recovered worms due to increases
in the solubility of the compound in this formulation; the greatest reduction (70.5%) was observed at the dose of 100mg/kg. There
was no changes in the pattern of mature egg compared to immature eggs; however there was a signiﬁcant increase in the number
of dead eggs. Histopathological analysis of liver tissue showed changes in morphological aspects of the hepatic parenchyma with
decrease exudative-productive hepatic granuloma stages, although we found no signiﬁcant diﬀerences in IFN-γ, IL-4, IL-10, or
NO production in response to the speciﬁc antigen SEA. The results show the derivative LPSF-PT05 to be a potential candidate in
the etiological treatment of schistosomiasis with a possible dampening eﬀect of the granulomatous process.
1.Introduction
Schistosomiasis is the second most signiﬁcant parasitic
disease in the world after malaria in terms of socioeconomic
and public health importance. It is estimated that 207
million people are infected in 74 countries throughout Latin
America, Africa, and Asia and more than 779 million people
are at risk of infection, with mortality estimated at up to
280,000 deaths annually in sub-Saharan Africa alone [1–3].
Estimates of the global burden of schistosomiasis range from
1.7 to 4.5 million disability-adjusted life years (DALYs) lost
[4–6]o re v e nh i g h e r[ 7].2 The Scientiﬁc World Journal
Chemotherapy is currently the main strategy in use for
schistosomiasis control. Praziquantel (2-cyclohexylcarbonyl-
1,2,3,6,7,11b-hexa-hydro-4H-pyrazino{2,1-a}isoquinoline-
4-one) is the drug of choice for the treatment of schistosomi-
asis because of its eﬃcacy against all schistosome species
[8, 9]. The control of Asian schistosomiasis has relied
on large-scale chemotherapy using the praziquantel [10].
However, mass treatment does not prevent reinfection [11].
Data assembled over the past ﬁve years suggest that
schistosomiasis is reemerging in parts of China [12].
Furthermore, despite the fact that there is not yet clear-cut
evidence for the existence of praziquantel-resistant schis-
tosome strains, decreased susceptibility to the drug has
been reported in several countries [11]. The reliance on one
single antischistosomal drug is alarming and the scientiﬁc
community has called for research and development of novel
and inexpensive drugs against schistosomiasis [13, 14].
The imidazolidines are a broad class of bioactive pentag-
onal heterocyclic compounds with diverse biological activity
[15]. The imidazolidine system has antifungal and antimi-
crobial properties [16], hypnotic [17], and hypoglycemic
[18, 19]e ﬀects.
Niridazole, 1-(5-nitro-thiazol-2-yl)-imidazolidin-2-one,
has been used over the past century for its schistosomicidal
properties. The drug received considerable attention, prob-
ably because it was one of the early treatment options to be
administered orally [20].
The schistosomicidal properties of imidazolidine deriva-
tives have been demonstrated by in vitro studies with
adult S. mansoni worms [21–25]. The 3-benzyl-5-(4-chloro-
arylazo)-4thioxo-imidazolidin-2-one, also known as LPSF-
PT05 (CAS Registry Number 197504-87-3) [26], used in this
work was synthesized by the Laborat´ orio de Planejamento e
S´ ı n t e s ed eF ´ armacos (LPSF) (UFPE) using diazonium ions
formed from a phenylamine that acts as an electrophilic
reagent and engages with the active hydrogen in position 5 of
3-benzyl-4thioxo-imidazolidine-2-one, yielding the arylazo
imidazolidine [27].
Recently, Neves and collaborators [28] demonstrated
the schistosomicidal activity in vitro of LPSF-PT05 with
signiﬁcantultrastructuralchangesinducedinwormsandless
cytotoxic eﬀect on splenocytes than praziquantel. Based on
this, the purpose of this study was to investigate the eﬀects of
LPSF-PT05, in vivo,a g a i n s ta d u l tw o r m so fS. mansoni. and
also the immunomodulating and histopathological eﬀects of
the granulomatous inﬂammation.
2.MaterialsandMethods
2.1.ParasitesandHosts. TheBH(BH—BeloHorizonte,MG,
Brazil) strain of S. mansoni that has been maintained in
the laboratory was used throughout this study. The strain
was kept after it had passed through Biomphalaria glabrata
molluscs provided by the Department of Tropical Medicine
(Universidade Federal de Pernambuco) and Swiss mice (Mus
musculus).
2.2. Animals. Swiss Webster mice females were used, average
weight 20 ± 2g and 5 weeks of age, and were bred and main-
tained at the Laborat´ orio de Imunopatologia Keizo Asami
(LIKA) of the Universidade Federal de Pernambuco, Recife,
Brazil. Animals were housed in a controlled temperature and
light environment and were given water and standard diet
ad libitum. The experiments were approved by the Federal
University of Pernambuco’s Animal Experiments Ethics
Committee, Process no. 009645/2006-23, in accordance with
Law 9605 Article 32 Decree 3179. Art 17.
Mice were infected by exposure to a cercarian suspension
of S. mansoni with approximately 100 ± 10 cercariae, using
the tail immersion technique [29].
2.3. Experimental Treatment. Animals previously selected
andproperlyweighedweresubmittedtoacommondietwith
freeaccesstowaterbeforetheadministrationofformulations
containing LPSF-PT05. In the ﬁrst formulation, 1% Tween
80 was used to solubilize LPSF-PT05 in a saline solution
(LPSF-PT05-Tween). The second formulation was prepared
in an oil/water (70:30) emulsion (LPSF-PT05-Emulsion).
The third formulation was a solid dispersion containing 10%
LPSF-PT05 in the hydrophilic polymer polyethylene glycol
(PEG) solubilized in water (LPSF-PT05-PEG).
The administration of the three formulations was done
orally, after 49 days of the infection, at a dose of 100mg/Kg
for 5 consecutive days. The solid dispersion containing
10% LPSF PEG-PT05 in three other doses (3, 10, and
30mg/kg) was administered. The controls groups, free of
LPSF-PT05, were submitted to the same testing conditions.
At 15 days posttreatment, the animals were euthanized by
cervical displacement.
2.4. Assessment of Parasitological Criteria. Worms were
recovered from the hepatic portal system and mesenteric
vessels using the perfusion technique described by Smithers
and Terry [30]. The percent of reduction in worm number
after treatment was calculated by the method of Tendler and
collaborators [31] as follows: % reduction = C − V/C × 100,
where C is the mean number of parasites recovered from
infected untreated animals and V is the mean number of
parasites recovered from treated animals.
Percentages at each egg developmental stage (oogram
pattern), the proportion of eggs at various stages of maturity
for the quantitative oogram test, were estimated following
theexperimentalmethoddescribedbyPellegrinoandcollab-
orators [32] .O n eh u n d r e de g g sp e ro o g r a mw e r er a n d o m l y
chosen,evaluatedbymicroscopicexamination,andclassiﬁed
as dead, immature, or mature for all infected untreated and
treated groups.
2.5. Culture of Spleen Cells. Spleen cell suspensions were pre-
pared from albino Swiss mice infected with S. mansoni and
treated with 3, 10, 30, or 100mg/kg of LPSF-PT05-PEG. The
suspensions were depleted of erythrocytes by hypotonic lysis
with distilled water and resuspended in RPMI 1640 complete
medium containing 5% FCS, 10mM L-glutamine, penicillinThe Scientiﬁc World Journal 3
Table 1: Eﬀect of diﬀerent formulations of LPSF-PT05 on worm burdens and oogram patterns in experimentally infected mice harbouring
adult S. mansoni (BH strain).
Group Dosing protocols
(mg/Kg × day)
Worm reductions % egg developmental stages
Total worms Total worms
reduction%
Total
Immature Mature Dead
Control (7) 24.60 ±16.29 — 58.88 ± 14.19 27.80 ±10.18 13.33 ±4.40
LPSF-PT05-Tween (7) 100 × 51 9 .43 ±7.87 21.0 47.50 ±7.37 27.93 ±5.49 24.58 ±7.97
Control (5) 30.43 ±12.20 50.72 ±6.14 29.52 ±4.16 19.71 ±5.51
LPSF-PT05-Emulsion (5) 100 × 51 8 .25 ±2.87 40.0 36.10 ± 12.68 31.67 ±4.35 32.23 ±14.57
Control (5) 26.50 ±12.34 57.51 ±1.17 34.16 ±3.53 8.330 ±2.36
LPSF-PT05-PEG (5)
100 × 57 .80 ±3.27 70.5# 35.34 ±7.05∗ 41.41 ±3.48 23.25 ±5.01#
30 × 51 4 .00 ±2.08 47.1# 49.17 ±6.06 24.38 ±4.87 26.46 ±4.66#
10 × 51 3 .80 ±4.43 47.9# 40.59 ± 15.46 33.33 ±12.02 26.10 ±3.48#
3 × 52 1 .25 ±3.40 19.8 53.76 ±5.99 28.33 ±3.60 16.66 ±2.35
The values are expressed in means ± SD. ∗P ≤ 0.05, #P ≤ 0.01 in comparison to control.
N u m b e r si nb r a c k e t sr e p r e s e n tt h en u m b e r so fm i c e .
(100U/mL), and streptomycin (100μg/mL) (Sigma Chemi-
cal, St. Louis, MO, USA). Spleen cells were cultured in 48-
wellﬂat-bottomplates(CorningCostar3548)at5 ×106 cells
per well and incubated at 37◦C and 5% CO2 f o r2 4a n d7 2
hours, under stimulation with 20μg/mL SEA (Schistosoma
mansonisolubleeggantigen).Supernatantsfromthecultures
were harvested for assessment of cytokine and NO levels. For
each experiment, the spleen cells of ﬁve mice were pooled.
2.6. Measurement of Nitrite Production and Detection of
Cytokines. Nitrite (NO2
−) accumulation in 72h super-
natants of cultured cells was used as an indicator of NO
production and was determined by the Griess reaction with
sodium nitrite as a standard, as previously described (detec-
tion limit: 1.56μM) [33]. Fifty microliters of supernatant
were incubated for 10min, in the dark, at room temperature,
with 50μL of a freshly mixed solution of N-[1-naphthyl]-
ethylenediamine (1mg/mL), sulfanilamide (10mg/mL), and
5% phosphoric acid in distilled water. The absorbance was
measured at 540nm. Production of IFN-γ, IL-10, and IL-
4 was measured in supernatants of spleen cell cultures
harvested after 24 or 72 hours, using a two-site sandwich
enzyme-linked immunosorbent assay (ELISA). Levels of IL-
4, IL-10, and IFN-γ in culture supernatants were deter-
mined using antibody pairs and recombinant cytokines from
PharMingen, following the manufacturer’s instructions, fol-
lowed by treatment with streptavidin-peroxidase (Sigma).
The reaction was developed using ABTS [(2,2 -azinobis (3-
ethylbenzthiazoline-6-sulfonic acid)] (Sigma Chemical, St.
Louis, MO, USA) as a peroxidase substrate and read at
405nm.
2.7. Histopathological Evaluation. Tissue samples of livers
were removed, ﬁxed immediately in 10% neutral-buﬀered
formalin, embedded in paraﬃn, and 5μms e c t i o n sw e r e
stained with Mayer’s hematoxylin and eosin [34]. The analy-
sis was performed using a video microscope system (LEICA
DMIL microscope, LEICA DFC 280 video-camera). Only
transverse sections of tissue samples showing granulomas
withvisibleeggsinthecenterwereanalyzed.Thegranulomas
were classiﬁed according to Costa-Silva et al. [35]; they
were discriminated in two granulomatous stages: exudative-
proliferative and involutional. Liver egg granulomas of ﬁve
mice were counted in ﬁve successive low power ﬁelds (10x)
per each group according to diﬀerent treatment.
2.8. Statistical Analysis. Results were expressed as mean ±
SEM. Data were statistically analyzed by one-way analysis of
variance, followed by the Mann-Whitney test for parasito-
logical and immunological studies and Student’s t-test for
histopathological study. Measurements with P values ≤ 0.05
were considered signiﬁcantly diﬀerent.
3. Results
Initially, oral doses of 100 mg/kg of the three formulations of
LPSF-PT05 was used to treat mice infected with Schistosoma
mansoni. The average worm burden was signiﬁcantly lower
than in the control group (P<0.05) when treatment was
done with LPSF-PT05-PEG with a mean reduction of worm
burden ranging from 19.8% to 70.5%. In groups treated with
LPSF-PT05-Tween and LPSF-PT05-emulsion, a reduction
rate was of 21% and 40%, respectively (Table 1).
The egg count test, although the absence of any one stage
of immature eggs was not seen by 15 days after the end of
treatment, we observed that the number of immature eggs
was lower in all formulations, with a signiﬁcant reduction
(at P<0.05 compared to its control) with the formulation
LPSF-PT05-PEG at a dose of 100mg/kg. This was inversely
proportional to the number of dead eggs, which increased in
all formulations and was also signiﬁcant (P<0.001) in the
treatment with the formulation LPSF-PT05-PEG at doses of
10, 30, and 100 mg/kg (Table 1).
To investigate the immunomodulating eﬀects of LPSF-
PT05-PEG, IFN-γ, IL-4, and IL-10 were quantiﬁed in
supernatants of spleen cell cultures using sandwich ELISA.
The NO production was determined by the Griess reaction.4 The Scientiﬁc World Journal
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Figure 1: IFN-γ (a), IL-4 (b), and nitric oxide (c) production by spleen cells after treatment of S. mansoni-infected mice with LPSF-PT05-
PEG. ∗P<0.001 in comparison with control.
As shown in Figure 1(a), treatment signiﬁcantly aﬀect
IFN-γ productioninculturesstimulatedwiththeeggantigen
in mice treated with 3mg/Kg and 30mg/Kg of the drug. IL-
4 in SEA-stimulated cultures was higher in cultures from
treated animals, but the levels of production of this cytokine
were not signiﬁcant (Figure 1(b)).
At this stage of infection, nitric oxide production was not
aﬀected by the treatment of infected animals. Control and
treated mice showed no signiﬁcant diﬀerence in their pro-
duction of NO. However, the cultures stimulated with SEA
showed higher production of nitric oxide for mice treated
with doses of 10, 30, and 100mg/kg, but the diﬀerence
was not statistically signiﬁcant (Figure 1(c)). Regarding IL-
10 production, this cytokine was below detection level in
spleen cell cultures for both control and treated mice.
Histopathological evaluation of eﬀect of LPSF-PT05-
PEG on granulomatous inﬂammation was measured in H&E
stained liver of mice infected by Schistosoma mansoni.
The analysis showed that treatment with LPSF-PT05-
PEG at doses of 10, 30, or 100mg/kg per day had a positive
eﬀect in reducing the liver damage caused by S. mansoni
infection, as shown by the reduced number of worms and
the downmodulation of granulomatous response (Figure 2),
thereby avoiding the development of host pathology.
Regarding general pathology, the eﬀects of periovular
schistosomal granulomas are dynamically similar to those of
wound healing, with production of granulation tissue that
becomeslessvascularizedovertime,whiletheﬁbrouscicatri-
cial tissue becomes more compact and mature. We observed
a decrease of the exudative-productive stages in the livers at
all concentrations of LPSF-PT05-PEG with a considerably
signiﬁcant decrease at doses of 10 and 100mg/kg (Figure 2
and Table 2).
4. Discussion
Chemotherapy is the mainstay of schistosomiasis control
and is carried out largely through the use of praziquantel.
The eﬃcacy of this compound against adult worms of
all schistosome species that infect humans has led to its
widespread use [8, 9]. The nearly complete reliance on praz-
iquantel for schistosomiasis control may hasten the selection
of drug-resistant parasites. The potential for development
of resistance to the conventional schistosomicidal drugs
has justiﬁed the search for new compounds. Several com-
pounds have shown promise for schistosomiasis therapy, for
example, artemether, protease inhibitors, 2-(alkylamino)-
1-phenyl-1-ethanethiosulfuric acids, and oxadiazoles with
emphasisonthe4-phenyl-1,2,5-oxadiazole-3-carbonitrile-2-
oxide [36–39].
The schistosomicidal eﬀect of imidazolidine derivatives
was ﬁrst reported in 1954 by Luttermoser and Bond [40],
who described the activity of 5,5-diphenylhydantoin and
5-(4-chlorophenyl)-5-methylhydantoin against Schistosoma
mansoni infections in mice. Other studies conﬁrmed modest
activity at toxic doses of 5,5-diphenylhydantoin, and 5-
(2,4,5-trichlorophenyl) hydantoin showed a potent schisto-
somicidal eﬀect [41].The Scientiﬁc World Journal 5
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Figure 2: Photomicrographs of granuloma stage in the livers of mice infected by S. mansoni. (a) Infected control exhibiting exudative-
productive stage granulomas (arrows) with a mature, viable egg in the center of the ﬁbrocellular granulomas. (b) LPSF-PT05-PEG (3mg/kg
per day); micrographs show well-circumscribed small ﬁbrocellular granulomas and marked ovum degeneration (asterisks). (c) LPSF-PT05-
PEG (10mg/kg per day); productive (arrow) and involutional (asterisk) granulomas stage. (d) LPSF-PT05-PEG (30mg/kg per day). (e)
LPSF-PT05-PEG (100mg/kg per day) involutional stage granulomas (asterisks). H&E, micrographs are at 100x magniﬁcation.
Table 2: Hepatic granulomas of mice infected by S.mansoni and treated with LPSF/PT05-PEG.
Granuloma stages Control 3mg/Kg 10mg/Kg 30mg/Kg 100mg/Kg
Exudative-productive 22.33 ±4.16 15.66 ±8.50 8.00 ±1.70∗ 20.66 ±5.80 11.00 ±1.00∗
Involutional 32.33 ±12.50 43.33 ±16.20 20.66 ±7.76 44.00 ±11.35 29.66 ±9.29
Animals per groups (n = 5). The values are expressed in means ± SD. Comparisons were made by Student’s t-test (∗P ≤ 0.05).6 The Scientiﬁc World Journal
More recently, evaluation of the schistosomicidal proper-
ties of the derivative 3-benzyl-5-(4-chloro-arylazo)-4thioxo-
imidazolidin-2-one, or LPSF-PT05, showed higher activity
in vitro against adult male worms, with 100% mortality
after 24 hours of contact at all the concentrations tested.
Maximal eﬃcacy against adult female worms was observed
after 72 hours. The relationship between the concentration
and the eﬀect obtained in a 24-hour period shows a dose-
dependent relationship. Electron microscopic observation of
the derivative LPSF/PT05 revealed alterations in the integu-
ment surface of the worms with the formation of bubbles
and peeling, indicating damage to cells; the magnitude
of eﬀect was directly related to the duration of exposure
[24, 28].
This in vitro study of LPSF-PT05 conﬁrmed the promis-
ing in vivo results. However, imidazolidinic compounds
present a limitation in their use due to their poor solubility
in water. One strategy used to overcome this inconvenience
was to create a complex of LPSF-PT05 with the hydrophilic
polymer PEG, which was then solubilized in water. This
f o r m u l a t i o np r o d u c e dar e d u c t i o ni nw o r mb u r d e no f7 0 . 5 %
compared to a 50% and 30% reduction in worm burden in
relation to formulations LPSF-PT05-Tween and LPSF-PT05-
emulsion,respectively.Thereducedburdenofresidualworm
was also seen in the pattern of egg count, when assessed 15
days after the end of treatment. This showed an increase in
the number of dead eggs and decrease in the number of
immature eggs which leads us to believe that LPSF-PT05-
PEG could have interfered with egg laying by female worms;
yet the time of observation adopted in this experiment did
not allow us to conﬁrm this suspicion.
The eﬀect achieved with the formulation of LPSF-
PT05-PEG nearly achieved the criterion established by the
World Health Organization to identify potential leaders
in the development of schistosomicidal compounds, which
is deﬁned as a highly active compound that produces a
reduction greater than 80% in worm burden after intraperi-
toneal administration of 100mg/kg repeated ﬁve times in
formulations with 10% DMSO [42]. Taking into account
the barriers in the process of absorption from oral admin-
istration, the LPSF-PT05-PEG, undoubtedly, has potential
as a schistosomicide. We believe that adjustments in dosing
schedule or even complexion with other adjuvants that
promote higher solubility can ensure the schistosomicidal
character of this imidazolidic compound.
Cellular immune response to S. mansoni has been inten-
sively studied because of the granulomatous response and
ﬁbrosis that occur during pathogenesis. Granulomas play a
protective role by sequestering hepatotoxins secreted by eggs
[43]; however, they also cause a cell-mediated inﬂammatory
response that results in the pathology of periportal ﬁbrosis
[44, 45] .T h ei m m u n er e s p o n s ei nS. mansoni infection has
been shown to be a T-cell-dependent mechanism, where the
hostinitiallyhasaTh1responseagainsttheearlystagesofthe
parasite [46]. After deposition of the eggs, the Th2 response
increases with IL-4 and IL-5 production [47]. The balance
of Th1 and Th2 cytokines is a determining factor in the
regulation of pathology and the formation of granulomas
and hepatic ﬁbrosis.
It has been reported that PZQ chemotherapy couldmod-
ulate humoral and cellular immune responses in individuals
infected by S. mansoni, probably due to destruction of
parasites and releasing of inﬂammatory stimulating factors
such as SEA [48]. In our previous results we observed
that praziquantel downregulated the IL-4, modulates IFN-γ
production, and increased IL-10 production in spleen cells
with 120 days of infection (data not shown).
We expected that LPSF-PT05 could also modulate
cytokine production after infect mice treatment. The present
study describes the eﬀects of treatment with LPSF-PT05-
PEG on the production of cytokines in response to SEA
and we found no signiﬁcant diﬀerences in IL-4, IL-10, and
nitric oxide production in response to the speciﬁc antigen
SEA. However, IFN-γ production in cultures stimulated with
the egg antigen in mice treated with 3mg/Kg and 30mg/Kg
of the drug was signiﬁcantly higher in comparison with
control group. In spite of these results we did not believe that
this IFN-γ higher production could aﬀect the evolution of
inﬂammatory response.
In the histopathological study of Schistosoma mansoni
infection, the eggs swept into the liver elicit T-cell-dependent
responses, which lead to macrophage activation and gran-
uloma formation around the eggs [49]. The severity of the
disease is determined by the number of eggs deposited in the
tissues and the extent of granuloma formation around them.
An important feature of murine schistosomiasis caused
by S. mansoni is granuloma immunomodulation, that is,
the spontaneous downregulation of the response to newly
deposited eggs with increased duration of infection [50, 51].
Immunomodulation has been linked to a decrease in T-cell
responses to egg antigens and is beneﬁcial to the host in
that it limits tissue injury and morbidity [52]. Although
we did not detect changes in the proﬁle of IFN-γ and IL-4
against the egg antigen, the treated animals sacriﬁced at 60
days following infection showed changes on morphological
aspects of the hepatic parenchyma of mice infected and
treated with LPSF-PT05-PEG, at a dose of 100mg/kg. At this
dosage, the involutional granuloma stages limit tissue injury.
The decrease in exudative-productive hepatic granuloma
stages was observed at all doses, but more so at 100mg/kg.
These results together suggest LPSF-PT05-PEG at a
dose of 100mg/Kg as a potential candidate for use in
schistosomiasis treatment. At this dose, we found a toxic
eﬀecttothewormsandanattenuationofgranulomapossibly
via immunomodulatory properties. Our next concern is to
prepare new formulations that can ensure greater solubility
of the compound at even lower doses, which would be ideal,
since it would minimize the occurrence of side eﬀects and
also evaluate the activity of PSF-PEG-PT05 on granuloma-
tous reaction in the chronic phase of schistosomiasis.
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